Clinical trials: Cell, Circulating Tumor
Head and Neck Cancer, Oral Cancer
Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Adjuvant CCRT
The aim 1 of this trial is the development of the Circulating tumor cells (CTCs) definition of oral cancer minimal residual disease (MRD), and aim 2 is a prospective trial of oral cancer treatment.
- Trial name
- NCT07296250
- Testing
- low-dose oral chemotherapy
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Neoplasms, Cancer
PRediction Of Five Usual Tumors Using Blood Test for Risk Assessment and Early Detection
Liquid biopsy technology based on cell-free nucleic acids and protein characteristics has unique advantages and significant application prospects in cancer early detection.
- Trial name
- PROFUTURE (NCT05874648)
- Testing
- Multi-cancer early detection test
- Where
- China
- Volunteers
- 3,830 people, healthy volunteers welcome
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Non Small Cell Lung Cancer
Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors
The goal of this observational study is to determine if liquid biopsies from patients with stage I non-small cell lung cancer (NSCLC) can add to the diagnosis of a small lung cancer, or can better detect recurrent lung cancer…
- Trial name
- SABR-DETECT (NCT05921474)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Nasopharyngeal Neoplasms
The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients
A circulating tumor cell (CTC) count is an established prognostic factor in some malignancies such as metastatic breast cancer. However, the value of CTC in diagnosis and outcome prediction of metastatic nasopharyngeal carcinoma…
- Trial name
- NCT02505139
- Testing
- the number of circulating tumor cells
- Volunteers
- 166 people
- Sponsor
- Sun Yat-sen University
Nonsmall Cell Lung Cancer
Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment
The purpose of this study is to determine whether it is feasible and safe to give research participants investigational treatment with durvalumab and tremelimumab after they have completed standard treatment for NSCLC and once…
- Trial name
- NCT04625699
- Testing
- Durvalumab, Tremelimumab
- Sponsor
- Catherine Shu
Triple Negative Breast Cancer
MicroRNA Profiles in Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) is an aggressive disease with higher proportion of Blacks affected and in younger age groups.
- Trial name
- TARMAC (NCT04771871)
- Testing
- Epirubicin, Cyclophosphamide, Paclitaxel
- Where
- 4 sites in Nigeria
- Volunteers
- 42 people
- Sponsor
- University College Hospital, Ibadan
Carcinoma, Non-small-cell Lung Cancer
Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients
Conduct a prospective study to confirm blood and urine ctDNA detection value in non-small-cell lung cancer patients.
- Conditions
- Carcinoma, Non-small-cell Lung Cancer, Lung Neoplasms
- Trial name
- NCT02696525
- Where
- 3 sites in China
- Volunteers
- 145 people
- Sponsor
- Peking University People's Hospital
Hepatocellular Carcinoma, Cirrhosis
Circulating Cell-free DNA-based Epigenetic Biomarker mSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis
Brief Summary (Plain-Language Version - Compliant with ClinicalTrials.gov Guidelines) The goal of this observational study is to learn whether a blood test called methylated SEPT9 (mSEPT9) can help diagnose hepatocellular…
- Trial name
- SEPT9_CROSS (NCT03311152)
- Testing
- "Epi proColon 2.0 CE" test from Epigenomics, Inc (Berlin, Germany)
- Where
- France
- Volunteers
- 639 people
- Sponsor
- Central Hospital, Nancy, France
Patients With High-risk Prostate Cancer
Circulating Tumor Cells in High-Risk Prostate Cancer Treated With High-dose Radiotherapy and Hormone Therapy
The detection and quantification of Circulating tumor cells CTCs in peripheral blood of patients with prostate adenocarcinoma may be useful at least for: Getting a correct stratification of patients with high-risk prostate cancer…
- Trial name
- NCT01800058
- Where
- 3 sites in Spain
- Volunteers
- 68 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Pancreatic Neoplasm
Cancer Stem Cell Specific Aptamer's Ability to Detect Blood Circulating Cancer Stem Cells and Its Role as a Predictor of Prognosis in Pancreatic Cancer
The treatment performance of pancreatic cancer has not changed significantly over the past 20 years and is still less than 10%. In addition, 80-90% of pancreatic cancer patients are found to be already advanced at the time of…
- Trial name
- NCT05745415
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Yonsei University
Circulating Tumor Cells, Pancreatic Adenocarcinoma
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.
Histological proof is a crucial and necessary step for appropriate care in oncology. In the case of pancreatic cancer, histological proof from pathological analysis of the surgical specimen is very rare due to the limited number…
- Conditions
- Circulating Tumor Cells, Pancreatic Adenocarcinoma, Circulating Tumor DNA (KRAS), CA 19.9
- Trial name
- CTC-Pancreas (NCT02072616)
- Testing
- Pancreatic adenocarcinoma diagnosis
- Where
- France
- Volunteers
- 101 people
- Sponsor
- University Hospital, Rouen
Myeloma Multiple
The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood
The main aim of this study is to evaluate the effectiveness of the clinical application of the XN-1000/20 hematology analyzer for risk stratification in patients with multiple myeloma based on the number of detected plasma cells…
- Trial name
- NCT04242121
- Testing
- fluorescence flow cytometry
- Where
- Russia
- Volunteers
- 24 people
- Sponsor
- Ivan S Moiseev
Prostate Cancer
Expression of Tumor Markers in Circulating Tumor Cells of Metastatic Hormone-sensitive Prostate Cancer
As prostate cancer progresses, tumor cells dissociate and enter the bloodstream. Considered a "liquid biopsy," these circulating tumor cells (CTC) can show how a patient's cancer evolves and responds to treatments.
- Trial name
- NCT02723526
- Testing
- Blood drawing
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
By doing this study, the research team would like to learn if using a blood test that measures the amount of tumor DNA in blood can help guide how to use chemotherapy combined with immunotherapy for individuals with head and neck…
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Neoplasms, Head Cancer
- Trial name
- NCT05420948
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Circulating Tumor Cell, Oropharyngeal Cancer
Prospective Study for the Prognostic and Predictive Role of Circulating Tumor Cells in Patients With Oropharyngeal Squamous Cell Carcinoma: CTCO (Circulating Tumor Cells in the Oropharynx)
Head and neck cancers (HNSCC) are primarily squamous cell cancers represented by tumors of the upper aerodigestive tract. Locally advanced stages (stages III and IV) account for 50 to 70% of all presentations.
- Trial name
- CTCO (NCT04696744)
- Testing
- CTC detection
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Hospices Civils de Lyon
Rectal Cancer Patients
Rectal Cancer CTC Trial
This prospective, multi-centre, randomised clinical trial aims to compare the effect of neoadjuvant chemoradiotherapy versus primary surgery on circulating tumor cells (CTCs) in patients with stage II-III rectal cancer without…
- Trial name
- NCT07194616
- Testing
- Primary Surgery, Neoadjuvant radiochemotherapy and surgery
- Where
- 4 sites in Czechia
- Volunteers
- 120 people
- Sponsor
- University Hospital Ostrava
Gastric Cancer, Gastro-oesophageal Junction Cancer
Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer
To explore the clinical value of dynamic detection of circulating tumor cells(CTCs), circulating tumor DNA(ctDNA) and cell-free DNA(cfDNA) in neoadjuvant chemotherapy and operation of resectable or locally advanced gastric or…
- Trial name
- NCT03957564
- Testing
- Neoadjuvant chemotherapy with PSOX regimen., Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in plasma., Detect the tumor related DNA in pathological tissues after operation.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Affiliated Hospital of Qinghai University
NeuroEndocrine Tumours
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
Circulating tumour cells (CTCs) are detectable in the blood in around 50% of patients with functioning NeuroEndocrine Tumours (NET) arising in the midgut area (tumours which are secreting hormones and are located in the area in…
- Trial name
- CALM-NET (NCT02075606)
- Testing
- lanreotide acetate
- Where
- 14 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Ipsen
Breast Neoplasms
Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer
The incidence of breast cancer in Chinese women has increased year by year, and luminal A breast cancer commonly occurs in early-stage and postmenopausal women.
- Trial name
- NCT04065321
- Testing
- PET-CT examination, Peripheral blood detection
- Where
- 2 sites in China
- Volunteers
- 500 people
- Sponsor
- Shengjing Hospital
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer
This phase II trial studies how well pembrolizumab works in treating patients with non-squamous non-small cell lung cancer which has spread to other places in the body.
- Trial name
- NCT02955758
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Joel Neal